What is Rapamycin?
Rapamycin is the longevity compound that serious practitioners point to when asked what they personally take. Peter Attia discusses it extensively, Bryan Johnson includes it in his protocol, and David Sinclair has referenced it. The Interventions Testing Program (ITP) — a rigorous multi-site NIH-funded study testing compounds for lifespan extension in genetically diverse mice — has replicated rapamycin's lifespan extension effect in multiple independent cohorts across multiple sites. It remains the most consistently replicated longevity intervention in mammalian biology.
Rapamycin works by inhibiting mTORC1 — the mechanistic target of rapamycin complex 1. mTOR is essentially a master growth and aging sensor: when nutrients are abundant, mTOR is active and drives anabolism (protein synthesis, cell growth, proliferation). When nutrients are scarce, mTOR is suppressed, triggering autophagy, cellular maintenance, and stress resistance programs. Chronically elevated mTOR — from constant nutrient availability in modern life — is associated with accelerated cellular aging, reduced autophagy, and increased age-related disease. Rapamycin inhibits mTORC1, mimicking the caloric restriction signal that extends lifespan in virtually every organism tested.
The key innovation in longevity use of rapamycin is intermittent dosing. The organ transplant protocol uses daily rapamycin to achieve continuous immunosuppression — which produces the well-known side effects of transplant immunosuppression (infection susceptibility, impaired wound healing, metabolic effects). The longevity protocol uses once-weekly rapamycin at lower doses, which transiently inhibits mTORC1 without the continuous immunosuppression of daily dosing. The intermittent approach is theorized to produce longevity benefits while avoiding the immune-related side effects — and this is what Peter Attia and most longevity physicians prescribe.
Human longevity evidence is meaningful but not a controlled trial. The PEARL study — a prospective human trial of rapamycin for aging — is ongoing. Studies in dogs (the Dog Aging Project) show benefits. But the landmark human RCT showing rapamycin extends human healthspan doesn't exist yet. What exists is strong mechanistic rationale, exceptional animal data, and a growing body of human safety and biomarker data from off-label use. For a complementary AMPK/mTOR-balancing perspective, see the MOTS-c page.
How it works
mTORC1 Inhibition — The Core
mTOR (mechanistic target of rapamycin) exists in two complexes: mTORC1 and mTORC2. Rapamycin selectively inhibits mTORC1 — the complex that integrates nutrient signals (amino acids, glucose, growth factors) to drive anabolic processes: ribosomal biogenesis and protein synthesis (via S6K1 and 4EBP1), cell growth and proliferation, lipid synthesis, and suppression of autophagy. When mTORC1 is inhibited by rapamycin, these anabolic programs are dialed down and the opposing programs — autophagy, cellular stress resistance, mitochondrial homeostasis — are upregulated. This shift mimics caloric restriction at the cellular signaling level.
Autophagy Induction
mTORC1 normally phosphorylates and inactivates ULK1, the autophagy-initiating kinase. Rapamycin inhibits mTORC1, releasing ULK1 to activate autophagy — the cellular recycling process that removes damaged proteins, organelles, and cellular debris. Reduced autophagy is one of the primary drivers of cellular aging across tissues, and rapamycin's restoration of autophagy activity is a central mechanism for its longevity effects.
Senescence and Inflammation
mTORC1 activity drives the SASP (senescence-associated secretory phenotype) — the pro-inflammatory secretome of senescent cells. Rapamycin reduces SASP by inhibiting the mTORC1-driven translation of inflammatory cytokines (IL-6, VEGF). This anti-SASP effect may complement senolytic approaches (such as FOXO4-DRI or dasatinib + quercetin) by reducing the inflammatory output of senescent cells that remain even after senolytic clearance.
Immune Remodeling — The Geroimmunoprotection Hypothesis
Paradoxically, intermittent rapamycin in elderly subjects has been shown to enhance rather than suppress immune function in some parameters. The Novartis/Mannick study found that a once-weekly mTOR inhibitor (RAD001/everolimus) improved vaccine responses in elderly subjects — suggesting that brief mTOR inhibition can rejuvenate age-impaired immune function. This geroimmunoprotective effect, distinct from the immunosuppression of daily transplant dosing, may be one of rapamycin's most important longevity mechanisms in older adults.
What the research shows
Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
Harrison DE et al.
Interventions Testing Program — three independent sites (JAX, UM, UT). Started at 600 days of age (roughly 60 human years), rapamycin raised age at 90% mortality by 14% in females and 9% in males; expressed as mean lifespan the effect sizes were 13% and 9% respectively. A second cohort beginning at 270 days also showed survival gains. One of the most important longevity papers in biology — the first evidence that mTOR signalling regulates mammalian lifespan, and that starting late still works.
View on PubMed →mTOR inhibition improves immune function in the elderly
Mannick JB et al.
218 elderly adults (65+) given the rapalog RAD001 (everolimus) for 6 weeks at 0.5 mg daily or 5 mg weekly, with influenza vaccine given two weeks after stopping. Vaccine response improved by about 20%, and the drug reduced the percentage of CD4 and CD8 T cells expressing PD-1, the inhibitory receptor that rises with age. First evidence that mTOR inhibition can enhance rather than suppress immune function in elderly humans.
View on PubMed →Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results
Moel M et al.
PEARL — the longest healthy-aging trial of actual rapamycin (not a rapalog) to date: 48 weeks, decentralized, double-blind, placebo-controlled, with 114 completers on weekly low-dose compounded rapamycin (5 or 10 mg) or placebo. Intermittent rapamycin was well tolerated, with adverse events similar to placebo. The primary endpoint (visceral fat) didn't move, but women on 10 mg gained lean muscle mass and reported less pain, and the 5 mg group reported better wellbeing — early human evidence that low-dose rapamycin can be taken safely for healthspan, with efficacy signals still to confirm in larger trials.
View on PubMed →What the community reports
Rapamycin's longevity community is among the most medically sophisticated — primarily physicians who prescribe it to themselves and patients, researchers in the longevity field, and serious longevity-focused biohackers who have done the research. The community is notably careful about the distinction between daily (transplant) and intermittent (longevity) dosing.
Common misconceptions
"Rapamycin is dangerous — it suppresses the immune system."
Daily rapamycin at transplant doses is powerfully immunosuppressive. Once-weekly low-dose rapamycin (5–6 mg) produces a brief mTOR inhibition pulse that the Mannick studies suggest actually enhances certain immune functions in elderly adults. These are different pharmacological situations — the immunosuppression concern applies to daily dosing, not the intermittent protocol used for longevity.
"Rapamycin will prevent muscle growth."
mTORC1 drives muscle protein synthesis — sustained inhibition does impair muscle growth. But once-weekly dosing produces intermittent inhibition; mTOR recovers within 24–48 hours and muscle protein synthesis is restored. Users who train most days and take rapamycin on a rest day, away from training, report minimal interference with muscle adaptations. Timing matters significantly.
"The mouse lifespan data directly predicts human lifespan extension."
The ITP mouse data is some of the most compelling longevity data in biology. But mice have different metabolic rates, aging biology, and cancer patterns than humans. The mouse data provides strong mechanistic support and motivates human study — it doesn’t prove human lifespan extension. The human longevity RCT doesn’t exist yet. This is honest and doesn’t diminish rapamycin’s standing as the most compelling longevity compound in the space.
Open PepperLedger to log your rapamycin protocol →
Free to join. No credit card. Ask the Researcher how rapamycin fits your longevity stack.
Free to join · No credit card · 23-day Pro trial included
Registered trials and extra catalog links. These are not Study cards — a registry page is not proof of efficacy.
- ClinicalTrials.gov · completed · NCT02874924Rapamycin mTOR inhibition in elderly metabolism
- ClinicalTrials.gov · completed · NCT04996719Rapamycin (Rapamune) to improve cardiac function in frail older adults